LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Prognostic Value and Reproducibility of AI-assisted Analysis of Lung Involvement in COVID-19 on Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials.

    Gieraerts, Christopher / Dangis, Anthony / Janssen, Lode / Demeyere, Annick / De Bruecker, Yves / De Brucker, Nele / van Den Bergh, Annelies / Lauwerier, Tine / Heremans, André / Frans, Eric / Laurent, Michaël / Ector, Bavo / Roosen, John / Smismans, Annick / Frans, Johan / Gillis, Marc / Symons, Rolf

    Radiology. Cardiothoracic imaging

    2020  Volume 2, Issue 5, Page(s) e200441

    Abstract: Purpose: To compare the prognostic value and reproducibility of visual versus AI-assisted analysis of lung involvement on submillisievert low-dose chest CT in COVID-19 patients.: Materials and methods: This was a HIPAA-compliant, institutional review ...

    Abstract Purpose: To compare the prognostic value and reproducibility of visual versus AI-assisted analysis of lung involvement on submillisievert low-dose chest CT in COVID-19 patients.
    Materials and methods: This was a HIPAA-compliant, institutional review board-approved retrospective study. From March 15 to June 1, 2020, 250 RT-PCR confirmed COVID-19 patients were studied with low-dose chest CT at admission. Visual and AI-assisted analysis of lung involvement was performed by using a semi-quantitative CT score and a quantitative percentage of lung involvement. Adverse outcome was defined as intensive care unit (ICU) admission or death. Cox regression analysis, Kaplan-Meier curves, and cross-validated receiver operating characteristic curve with area under the curve (AUROC) analysis was performed to compare model performance. Intraclass correlation coefficients (ICCs) and Bland- Altman analysis was used to assess intra- and interreader reproducibility.
    Results: Adverse outcome occurred in 39 patients (11 deaths, 28 ICU admissions). AUC values from AI-assisted analysis were significantly higher than those from visual analysis for both semi-quantitative CT scores and percentages of lung involvement (all P<0.001). Intrareader and interreader agreement rates were significantly higher for AI-assisted analysis than visual analysis (all ICC ≥0.960 versus ≥0.885). AI-assisted variability for quantitative percentage of lung involvement was 17.2% (coefficient of variation) versus 34.7% for visual analysis. The sample size to detect a 5% change in lung involvement with 90% power and an α error of 0.05 was 250 patients with AI-assisted analysis and 1014 patients with visual analysis.
    Conclusion: AI-assisted analysis of lung involvement on submillisievert low-dose chest CT outperformed conventional visual analysis in predicting outcome in COVID-19 patients while reducing CT variability. Lung involvement on chest CT could be used as a reliable metric in future clinical trials.
    Language English
    Publishing date 2020-10-22
    Publishing country United States
    Document type Journal Article
    ISSN 2638-6135
    ISSN (online) 2638-6135
    DOI 10.1148/ryct.2020200441
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prognostic Value and Reproducibility of AI-assisted Analysis of Lung Involvement in COVID-19 on Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials

    Gieraerts, Christopher / Dangis, Anthony / Janssen, Lode / Demeyere, Annick / De Bruecker, Yves / De Brucker, Nele / van Den Bergh, Annelies / Lauwerier, Tine / Heremans, André / Frans, Eric / Laurent, Michaël / Ector, Bavo / Roosen, John / Smismans, Annick / Frans, Johan / Gillis, Marc / Symons, Rolf

    Radiol Cardiothorac Imaging

    Abstract: PURPOSE: To compare the prognostic value and reproducibility of visual versus AI-assisted analysis of lung involvement on submillisievert low-dose chest CT in COVID-19 patients. MATERIALS AND METHODS: This was a HIPAA-compliant, institutional review ... ...

    Abstract PURPOSE: To compare the prognostic value and reproducibility of visual versus AI-assisted analysis of lung involvement on submillisievert low-dose chest CT in COVID-19 patients. MATERIALS AND METHODS: This was a HIPAA-compliant, institutional review board-approved retrospective study. From March 15 to June 1, 2020, 250 RT-PCR confirmed COVID-19 patients were studied with low-dose chest CT at admission. Visual and AI-assisted analysis of lung involvement was performed by using a semi-quantitative CT score and a quantitative percentage of lung involvement. Adverse outcome was defined as intensive care unit (ICU) admission or death. Cox regression analysis, Kaplan-Meier curves, and cross-validated receiver operating characteristic curve with area under the curve (AUROC) analysis was performed to compare model performance. Intraclass correlation coefficients (ICCs) and Bland- Altman analysis was used to assess intra- and interreader reproducibility. RESULTS: Adverse outcome occurred in 39 patients (11 deaths, 28 ICU admissions). AUC values from AI-assisted analysis were significantly higher than those from visual analysis for both semi-quantitative CT scores and percentages of lung involvement (all P<0.001). Intrareader and interreader agreement rates were significantly higher for AI-assisted analysis than visual analysis (all ICC ≥0.960 versus ≥0.885). AI-assisted variability for quantitative percentage of lung involvement was 17.2% (coefficient of variation) versus 34.7% for visual analysis. The sample size to detect a 5% change in lung involvement with 90% power and an α error of 0.05 was 250 patients with AI-assisted analysis and 1014 patients with visual analysis. CONCLUSION: AI-assisted analysis of lung involvement on submillisievert low-dose chest CT outperformed conventional visual analysis in predicting outcome in COVID-19 patients while reducing CT variability. Lung involvement on chest CT could be used as a reliable metric in future clinical trials.
    Keywords covid19
    Publisher PMC
    Document type Article ; Online
    DOI 10.1148/ryct.2020200441
    Database COVID19

    Kategorien

  3. Article ; Online: Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.

    Vermeersch, Kristina / Gabrovska, Maria / Aumann, Joseph / Demedts, Ingel K / Corhay, Jean-Louis / Marchand, Eric / Slabbynck, Hans / Haenebalcke, Christel / Haerens, Michiel / Hanon, Shane / Jordens, Paul / Peché, Rudi / Fremault, Antoine / Lauwerier, Tine / Delporte, Anja / Vandenberk, Bert / Willems, Rik / Everaerts, Stephanie / Belmans, Ann /
    Bogaerts, Kris / Verleden, Geert M / Troosters, Thierry / Ninane, Vincent / Brusselle, Guy G / Janssens, Wim

    American journal of respiratory and critical care medicine

    2019  Volume 200, Issue 7, Page(s) 857–868

    Abstract: Rationale: ...

    Abstract Rationale:
    MeSH term(s) Administration, Inhalation ; Adrenergic beta-Agonists/therapeutic use ; Aged ; Anti-Bacterial Agents/therapeutic use ; Azithromycin/therapeutic use ; Clindamycin/therapeutic use ; Disease Progression ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Forced Expiratory Volume ; Glucocorticoids/therapeutic use ; Hospitalization ; Humans ; Macrolides/therapeutic use ; Male ; Middle Aged ; Mortality ; Muscarinic Antagonists/therapeutic use ; Patient Readmission ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinolones/therapeutic use ; Treatment Failure ; Vital Capacity ; beta-Lactams/therapeutic use
    Chemical Substances Adrenergic beta-Agonists ; Anti-Bacterial Agents ; Glucocorticoids ; Macrolides ; Muscarinic Antagonists ; Quinolones ; beta-Lactams ; Clindamycin (3U02EL437C) ; Azithromycin (83905-01-5)
    Language English
    Publishing date 2019-05-03
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.201901-0094OC
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top